Supreme Court Denies Norwich Bid For US Xifaxan Reprieve
Refuses Request For Certiorari Over Skinny-Label Rifaximin Generic
The US Supreme Court has failed to come to the aid of Norwich Pharmaceuticals in its legal battle over a generic version of Xifaxan (rifaximin) that has a patented indication carved out of its label. An earlier decision over the generic thus bars approval and launch until 2029.
